Search and Filter Protocols

Use the checkboxes and search input field to locate the relevant protocol.

To filter by categories, simply select the relevant categories and/or statuses and click "submit" (without entering any text into the search field).

To search by Protocol name, simply enter it into the search box and click "submit".

  • Disease Categories

*NOTE* if there are categories that have no protocols attached, they will not show up as a checkbox for filtering. For example, if "Head and Neck" is not available as a disease category checkbox selection, there are no protocols that have that disease category assigned.

All Current Protocols Arranged Alphabetically by Disease Category:

Brain

ALLIANCE A071401

Primary Category:

Treatment Protocols

Disease Category:

Brain

Status:

Open

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations

NCT#02523014

A071401 Cohorts NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) are closed to new patient registration (Step 1) to abemaciclib cohort, effective October 3, 2022.

ALLIANCE A071601

Primary Category:

Treatment Protocols

Disease Category:

Brain

Status:

Open

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

NCT#03224767

ALLIANCE A071701

Primary Category:

Treatment Protocols

Disease Category:

Brain, Brain Metastatic, Molecular Profiling

Status:

Open

Genomically-Guided Treatment Trial in Brain Metastases

NCT#03994796

A071701-Eentrectinib (NTRK/ROS1) Cohort is closed to accrual of new patients (Step 1) effective January 9, 2024.

ALLIANCE A071702

Primary Category:

Treatment Protocols

Disease Category:

Brain

Status:

Temporarily Closed

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma

A071702 is temporarily closed to new patient pre-registration (Step 0), effective December 12, 2023.

NCT#04145115

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ALLIANCE CCTG CE.7

Primary Category:

Radiation Oncology

Disease Category:

Brain, Brain Metastatic

Status:

Open

A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) plus Memantine for 5-15 Brain Metastases

Eligible for screening study DCP 001

NCT#03550391

ALLIANCE N0577

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Open

(CODEL) Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Eligible for screening study DCP 001

NCT#00887146

 

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

NRG BN003

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Open

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Eligible for screening study DCP 001

NCT#03180268

 

NRG BN010

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Open

A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

NCT#04729959

BN010, dose level 3 is reopened to accrual, effective February 6, 2024, with the implementation of Amendment 3.

 

NRG BN011

Primary Category:

Treatment Protocols

Disease Category:

Brain

Status:

New, Open

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

NCT#05095376

 

NRG BN012

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

Brain, Brain Metastatic

Status:

Open

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases

Eligible for screening study DCP 001

NCT#05438212

NRG CC009

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain, Lung, Lung - Small Cell

Status:

Open

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

Eligible for screening study DCP 001

NCT#04804644

 

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

WAKE FOREST WF-2201

Primary Category:

Radiation Oncology

Disease Category:

Brain Metastatic, Breast, Breast Metastatic, Genitourinary, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Melanoma, Metastatic Melanoma, Renal, Renal Metastatic, Skin

Status:

New, Open

Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE)

NCT#05703269

Eligible for screening study DCP 001

Breast

ALLIANCE A011801

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Eligible for screening study DCP 001

NCT#04457596

ALLIANCE A012103

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

New, Open

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Eligible for screening study DCP 001

NCT#05812807

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A191901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Temporarily Closed

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Eligible for screening study DCP 001

NCT#04379570

A191901 is temporarily closed to accrual, effective November 16, 2022.

A191901 is permanently closed to accrual of non-Black women over 50, effective February 25, 2022 at 4:30pm (ET)

A191901 is permanently closed to accrual of non-Black women, effective April 15, 2022 at 4:30pm (ET)

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EA1151

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast

Status:

Open

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Limited institution study: open only to Saint Alphonsus Health System.

NCT#03233191

Eligible for screening study DCP 001

 

 

ECOG-ACRIN EAQ221CD

Primary Category:

Cancer Care Delivery

Disease Category:

Breast, Breast Metastatic

Status:

New, Open

Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP)

NCT#06112613

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

NRG BR007

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Breast

Status:

Open

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT#04852887

Eligible for screening study DCP 001

BR007, HRQOL Sub-study, is closed to accrual, effective April 24, 2023.

 

NRG BR008

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Adjuvant Breast, Breast, Breast Neoadjuvant

Status:

New, Open

A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)

NCT#05705401

Eligible for screening study DCP 001

NRG BR009

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

New, Open

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score

NCT#05879926

NRG CCTG MA.39

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

Eligible for screening study DCP 001

For CCTG MA.39, please credit NRG all accruals.

CCTG MA.39-Optional Questionnaire Component is closed to accrual effective August 2, 2022

NCT#03488693

NRG EAY191-N2

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

New, Open

Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial

NCT#05554354

(See required screening study ECOG-ACRIN EAY191)

SWOG S1501

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Temporarily Closed

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Eligible for screening study DCP 001

NCT#03418961

S1501 is temporarily closed to accrual, effective February 1, 2024 at 12pm Pacific Time.

S1501,  Arm 3 is permanently closed to accrual, effective July 29, 2021, at 11:59pm Pacific Time.

SWOG S1703

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

NCT#03723928

Eligible for screening study DCP 001

SWOG S1706

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

NCT#03598257

SWOG S2007

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

NCT#04647916

 

 

SWOG S2010

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

New, Open

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)

Eligible for screening study DCP 001

NCT#05568472

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

SWOG S2206

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

New, Open

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

NCT#06058377

SWOG S2212

Primary Category:

Surgical Protocols, Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

New, Open

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

NCT#05929768

WAKE FOREST WF-2201

Primary Category:

Radiation Oncology

Disease Category:

Brain Metastatic, Breast, Breast Metastatic, Genitourinary, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Melanoma, Metastatic Melanoma, Renal, Renal Metastatic, Skin

Status:

New, Open

Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE)

NCT#05703269

Eligible for screening study DCP 001

Cancer Care Delivery

SWOG S1912CD

Primary Category:

Cancer Care Delivery

Disease Category:

Cancer Care Delivery

Status:

Open

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

Eligible for screening study DCP 001

NCT#04960787

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Gastrointestinal

ALLIANCE A022004

Primary Category:

Treatment Protocols

Disease Category:

Colon, Gastrointestinal

Status:

New, Open

Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer

NCT#05710406

ALLIANCE A022101

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic

Status:

New, Open

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)

NCT#05673148

Eligible for screening study DCP 001

ALLIANCE A022104

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Gastrointestinal, Rectal

Status:

New, Open

The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer

NCT#05610163

 

ALLIANCE A022106

Primary Category:

Treatment Protocols

Disease Category:

Gastrointestinal, Pancreatic, Pancreatic Metastatic

Status:

New, Open

ProtocolPhase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

NCT#06115499

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A221805

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Colon, Gastrointestinal, Rectal

Status:

Open

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Eligible for screening study DCP 001

A221805 is reopened to accrual to the Phase III portion with the implementation of Update 5, effective 02/20/24

A221805, Phase II, is closed to accrual effective March 31, 2023, at 4:30 ET.  If interim analysis is positive, Phase III will open to accrual.

A221805-Substudy SI1 is closed to accrual, effective September 15, 2022, at 4:30pm ET.

NCT#04137107

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ALLIANCE EAY191-A6

Primary Category:

Treatment Protocols

Disease Category:

Cholangiocarcinoma, Gallbladder, Gastrointestinal

Status:

Open

FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05564403

ECOG-ACRIN EA2176

Primary Category:

Treatment Protocols

Disease Category:

Anal, Gastrointestinal

Status:

Open

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

Eligible for screening study DCP 001

NCT#04444921

 

ECOG-ACRIN EA2182

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Anal, Gastrointestinal

Status:

Open

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

NCT#04166318

ECOG-ACRIN EA2183

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Esophageal, Esophageal Metastatic, Gastrointestinal, Stomach, Stomach Metastatic

Status:

Temporarily Closed

A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

NCT#04248452

Eligible for screening study DCP 001

EA2183 is temporarily closed to accrual, effective March 12, 2024.

ECOG-ACRIN EA2201

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Gastrointestinal, Rectal

Status:

Temporarily Closed

A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

NCT#04751370

EA2201 is temporarily closed to accrual, effective May 9, 2023.

 

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-A3

Primary Category:

Treatment Protocols

Disease Category:

Gastrointestinal, Gynecologic, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic

Status:

New, Open

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554367

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

NRG GI004

Primary Category:

Treatment Protocols

Disease Category:

Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic

Status:

Open

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Eligible for screening study DCP 001

NRG GI004 reopened to accrual effective January, 29, 2021.

NCT#02997228

Site Delegation of Tasks Log required prior to registration of any patients.

NRG GI008

Primary Category:

Treatment Protocols

Disease Category:

Colon

Status:

Open

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)

NCT#05174169

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S1922

Primary Category:

Treatment Protocols

Disease Category:

Gastrointestinal, Small Bowel

Status:

Open

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

NCT#04205968

SWOG S2001

Primary Category:

Treatment Protocols

Disease Category:

Pancreatic, Pancreatic Metastatic

Status:

Open

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

NCT#04548752

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2107

Primary Category:

Treatment Protocols

Disease Category:

Colon, Colon Metastatic, Rectal, Rectal Metastatic

Status:

Open

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

NCT#05308446

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Genitourinary

ALLIANCE A031701

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

Open

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

NCT#03609216

ALLIANCE A031702

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary, Prostate, Renal

Status:

Open

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

NCT#03866382

 

ALLIANCE A031704

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Renal, Renal Metastatic

Status:

Open

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Eligible for screening study DCP 001

NCT#03793166

ALLIANCE A031801

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Genitourinary, Renal, Renal Metastatic

Status:

Open

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)

NCT#04071223

ALLIANCE A031803

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

Open

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NCT#04164082

A031803 is reopened to accrual with implementation of Update 8, effective April 18, 2023.

ALLIANCE A032101

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Prostate, Prostate Metastatic

Status:

New, Open

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM

NCT#05241860

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EA8171

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

Open

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

NCT#03697148

ECOG-ACRIN EA8191

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

Open

Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Eligible for screening study DCP 001

NCT#04423211

 

ECOG-ACRIN EA8212

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

New, Open

A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Eligible for screening study DCP 001

NCT#05538663

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

ECOG-ECRIN EA8211

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Genitourinary, Renal, Renal Metastatic

Status:

New, Open

Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)

NCT#05863351

NRG GU007

Primary Category:

Radiation Oncology

Disease Category:

Genitourinary, Prostate

Status:

Temporarily Closed

Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (with Initial Phase I)

NCT#04037254

GU007 is temporarily closed to accrual to phase I/dose level 3, effective August 1, 2023.

GU007 Phase II is not open to accrual as of January 27, 2022.

NRG GU008

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

Open

Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy

NCT#04134260

Eligible for screening study DCP 001

GU008 is reopened to accrual upon implementation of Amendment 2, effective December 7, 2021.

NRG GU009

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Prostate

Status:

Open

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)

Eligible for screening study DCP 001

Closure of Accrual for QOL Substudy for pateints enrolled in Arms 1 and 2, effective September 22, 2023

Optional Imaging Sub Study is temporarily closed accrual, effective December 21, 2021

NCT#04513717

NRG GU010

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Prostate

Status:

Open

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)

NCT#05050084

NRG GU013

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

New, Open

The Phase III `High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer

NCT#05946213

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S1802

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

Genitourinary, Prostate, Prostate Metastatic

Status:

Open

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

NCT#03678025

Eligible for screening study DCP 001

SWOG S1937

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary

Status:

Open

A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

S1937 , Arms 1 & 3  are reopened with the implementation of Revision 3 effective Feburary 20, 2024.  

S1937, Arm 2 is closed to accrual, effective February 15, 2024.

Eligible for screening study DCP 001

NCT#04579224

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

SWOG S2210

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

New, Open

A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations

NCT#05806515

WAKE FOREST WF-2201

Primary Category:

Radiation Oncology

Disease Category:

Brain Metastatic, Breast, Breast Metastatic, Genitourinary, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Melanoma, Metastatic Melanoma, Renal, Renal Metastatic, Skin

Status:

New, Open

Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE)

NCT#05703269

Eligible for screening study DCP 001

Gynecologic

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-A3

Primary Category:

Treatment Protocols

Disease Category:

Gastrointestinal, Gynecologic, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic

Status:

New, Open

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554367

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

NRG CC008

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Ovarian

Status:

Open

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Eligible for screening study DCP 001

CC008-Temporary Closure to Accrual for BSO 35-<42 Age Block, effective December 7, 2023.

NCT#04251052

NRG EAY191-N4

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Endometrial Metastatic, GYN Other, Gynecologic, Ovarian, Ovarian Metastatic

Status:

Open

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

NCT#05554328

(See required screening study ECOG-ACRIN EAY191)

NRG EAY191-N5

Primary Category:

Treatment Protocols

Disease Category:

Cervical, Cervical Metastatic, Endometrial, Endometrial Metastatic, GYN Other, Gynecologic, Ovarian, Ovarian Metastatic, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#06126276

NRG GY019

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian, Ovarian Metastatic

Status:

Open

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Eligible for screening study DCP 001

NCT#04095364

NRG GY024

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

GYN Other, Gynecologic

Status:

Open

Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial

NCT#05076942

NRG GY026

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Endometrial Metastatic, Gynecologic

Status:

Open

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

NCT#05256225

NRG GY033

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian

Status:

New, Open

A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor

NCT#06169124

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Head and Neck

ALLIANCE A092105

Primary Category:

Treatment Protocols

Disease Category:

Head and Neck, Head and Neck Metastatic

Status:

New, Open

Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

NCT#05904080

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EA3161

Primary Category:

Treatment Protocols

Disease Category:

Head and Neck

Status:

Open

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC

NCT#03811015

ECOG-ACRIN EA3163

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

Head and Neck

Status:

Open

Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a (and selected T4b) nasal and paranasal sinus squamous cell carcinoma (NPNSCC)

NCT#03493425

Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21

ECOG-ACRIN EA3191

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Head and Neck

Status:

Open

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

NCT#04671667

EA3191 is reopened to accrual with the implementation of Addendum 6, effective April 18, 2023

 

ECOG-ACRIN EA3211

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Head and Neck, Head and Neck Metastatic

Status:

New, Open

Phase III Randomized Trial of Immunotherapy with or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

NCT#05721755

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

NRG HN005

Primary Category:

Radiation Oncology

Disease Category:

Head and Neck

Status:

Temporarily Closed

A Randomized Phase II/II Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

HN005 is temporarily closed to accrual effective November 8, 2023, at 5pm ET

Open to Phase II enrollment

NCT#03952585

NRG HN009

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Head and Neck, Head and Neck Metastatic

Status:

New, Open

Randomized Phase II/III Trial of Radiation with Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation with Weekly Cisplatin at 40 mg/m2 for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT#05050162

NRG HN011

Primary Category:

Treatment Protocols

Disease Category:

Head and Neck, Head and Neck Metastatic

Status:

New, Open

A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

NCT#06029270

NRG R1216

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Head and Neck

Status:

Open

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

NCT#01810913

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Leukemia

ALLIANCE A041501

Primary Category:

Treatment Protocols

Disease Category:

Acute Lymphocytic Leukemia, Leukemia

Status:

Temporarily Closed

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL

NCT#03150693

Eligible for screening study DCP 001

Temporary suspension effective May 24, 2022 due to Alliance DSMB review.

Confirmation of Tolerability Phase and slot reservation completed and study currently open to Phase III enrollment as of 06/12/2018.  See Section 4.4 for registration and randomization instructions.

ALLIANCE A041701

Primary Category:

Treatment Protocols

Disease Category:

Acute Myeloid Leukemia, Leukemia

Status:

Temporarily Closed

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

NCT#03701308

ALLIANCE A042001

Primary Category:

Treatment Protocols

Disease Category:

Acute Myeloid Leukemia, Leukemia, Lymphoma, Non-Hodgkin Lymphoma

Status:

New, Open

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

NCT#05303792

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ECOG-ACRIN EA9171

Primary Category:

Treatment Protocols

Disease Category:

Chronic Myeloid Leukemia, Leukemia

Status:

Open

BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD

NCT#03516279

EA9171 is reopened to accrual with the implementation of Addendum 10, effective April 18, 2023

ECOG-ACRIN NHLBI-MDS

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Leukemia, Myelodysplastic Syndrome

Status:

Open

The National Myelodysplastic Syndromes (MDS) Study

 

NCT#02775383

Eligible for screening study DCP 001

This protocol has additional regulatory requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.

Suspension to enrollment of new participants and follow-up research sample collection and shipment is lifted effective May 18, 2020, for NHLBI-MDS.  Refer to memo dated March 27, 2020, on conducting remote follow-up data for enrolled participants.

SWOG S1925

Primary Category:

Treatment Protocols

Disease Category:

Chronic Lymphocytic Leukemia, Lymphoma

Status:

Open

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Eligible for screening study DCP 001

NCT#04269902

 

Lung

ALLIANCE A081801

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell

Status:

Open

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

(See required screening study ALLIANCE A151216)

NCT#04267848

A081801 is reopened to accrual with the implementation of Update 9, effective April 18, 2023.

ALLIANCE A151216

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Molecular Profiling

Status:

Open

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105 (closed), A081801E4512, and EA5142 (closed).

Eligible for screening study DCP 001

Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.

NCT#02194738

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN E4512

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Molecular Profiling

Status:

Open

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

(See required screening study ALLIANCE A151216)

Eligible for screening study DCP 001

NCT#02201992

 

ECOG-ACRIN EA5162

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

NCT#03191149

EA5162 is reopened to accrual, effective December 20, 2022.

ECOG-ACRIN EA5182

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Eligible for screening study DCP 001

NCT#04181060

ECOG-ACRIN EA5221

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

New, Open

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

NCT#06096844

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

NRG CC009

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain, Lung, Lung - Small Cell

Status:

Open

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

Eligible for screening study DCP 001

NCT#04804644

 

NRG LU004

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell

Status:

Open

Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined with MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

LU004 is reopened to accrual with implementation of Amendment 6, effective January 16, 2024.

NCT#03801902

NRG LU007

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage

Status:

Open

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

NCT#04402788

 

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG LUNGMAP

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
A screening trial for S1800A (closed), S1900A (closed), S1900C (closed), S1900E, S1900F, S1900G, and S1900K.

NCT#03851445

Eligible for screening study DCP 001

LUNGMAP participants with KRASG12c and TP53 mutations and Wild Type STK11, KEAP1, NFE2L2, AND CUL3 will no longer be assigned to S1900E, effective December 13, 2023.

Effective, June 30th, 2019, the sub-study S1400GEN is closed to accrual.

SWOG S1827

Primary Category:

Radiation Oncology

Disease Category:

Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage

Status:

Open

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Eligible for screening study DCP 001

NCT#04155034

SWOG S1900E

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

See Screening Protocol LUNGMAP

S1900E, Cohort 1 is closed to accrual effective December 13, 2023 at 12:00 p.m. PST.

LUNGMAP participants with KRASG12c and TP53 mutations and Wild Type STK11, KEAP1, NFE2L2, AND CUL3 will no longer be assigned to S1900E, effective December 13, 2023.

NCT#04625647

 

SWOG S1900G

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell Metastatic

Status:

Open

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

See Screening Protocol LUNGMAP

NCT#05642572

SWOG S1900K

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

New, Open

A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

NCT#06031688

See Screening Protocol LUNGMAP

SWOG S1914

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell

Status:

Open

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Eligible for screening study DCP 001

NCT#04214262

SWOG S1933

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung - Non-Small Cell

Status:

Open

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

NCT#04310020

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

SWOG S2302

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

New, Open

Pragmatica – Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Eligible for screening study DCP 001

NCT#05633602

WAKE FOREST WF-2201

Primary Category:

Radiation Oncology

Disease Category:

Brain Metastatic, Breast, Breast Metastatic, Genitourinary, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Melanoma, Metastatic Melanoma, Renal, Renal Metastatic, Skin

Status:

New, Open

Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE)

NCT#05703269

Eligible for screening study DCP 001

Lymphoma

ALLIANCE A042001

Primary Category:

Treatment Protocols

Disease Category:

Acute Myeloid Leukemia, Leukemia, Lymphoma, Non-Hodgkin Lymphoma

Status:

New, Open

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

NCT#05303792

ALLIANCE A051902

Primary Category:

Treatment Protocols

Disease Category:

Lymphoma, Non-Hodgkin Lymphoma

Status:

Open

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

NCT#04803201

A051902 is open to accrual to the Randomized Phase II Safety check portion of the study, effective September 18. 2023.

ALLIANCE A052101

Primary Category:

Treatment Protocols

Disease Category:

Lymphoma, Mantle Cell Lymphoma

Status:

Open

A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma

NCT#05976763

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EA4151

Primary Category:

Treatment Protocols

Disease Category:

Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma

Status:

Open

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

NCT#03267433

Eligible for screening study DCP 001

Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S1608

Primary Category:

Treatment Protocols

Disease Category:

Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

Status:

Open

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

S1608 is reopened to accrual, effective March 10, 2023,  at 12:00 pm Pacific Time.

NCT#03269669

SWOG S1925

Primary Category:

Treatment Protocols

Disease Category:

Chronic Lymphocytic Leukemia, Lymphoma

Status:

Open

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Eligible for screening study DCP 001

NCT#04269902

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

Molecular Profiling

ALLIANCE A071701

Primary Category:

Treatment Protocols

Disease Category:

Brain, Brain Metastatic, Molecular Profiling

Status:

Open

Genomically-Guided Treatment Trial in Brain Metastases

NCT#03994796

A071701-Eentrectinib (NTRK/ROS1) Cohort is closed to accrual of new patients (Step 1) effective January 9, 2024.

ALLIANCE A151216

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Molecular Profiling

Status:

Open

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105 (closed), A081801E4512, and EA5142 (closed).

Eligible for screening study DCP 001

Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.

NCT#02194738

ECOG-ACRIN E4512

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Molecular Profiling

Status:

Open

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

(See required screening study ALLIANCE A151216)

Eligible for screening study DCP 001

NCT#02201992

 

ECOG-ACRIN EAY131-K2

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions

(See required screening study ECOG-ACRIN EAY131)

Open  to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.

The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

Effective today, July 18th, 2019, Subprotocol K2: Phase 2 is suspended due to the completion of accrual.

NCT#02465060

ECOG-ACRIN EAY131-M

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

(See required screening study ECOG-ACRIN EAY131)

EAY131 Subprotocol M is temporarily closed to accrual, effective August 3, 2021

Open  to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.

The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

NCT#02465060

ECOG-ACRIN EAY131-Z1M

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy

(See required screening study ECOG-ACRIN EAY131)

Accrual to EAY131-Z1M is suspended, effective January 17,2023.

NCT#02465060

 

 

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Multiple Myeloma

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EAA173

Primary Category:

Treatment Protocols

Disease Category:

Multiple Myeloma

Status:

Open

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Eligible for screening study DCP 001

NCT#03937635

ECOG-ACRIN EAA181

Primary Category:

Treatment Protocols

Disease Category:

Multiple Myeloma

Status:

Open

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Eligible for screening study DCP 001

NCT#04566328

 

ECOG-ACRIN EAQ221CD

Primary Category:

Cancer Care Delivery

Disease Category:

Breast, Breast Metastatic

Status:

New, Open

Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP)

NCT#06112613

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

NRG EAY191-N2

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

New, Open

Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial

NCT#05554354

(See required screening study ECOG-ACRIN EAY191)

SWOG S1501

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Temporarily Closed

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Eligible for screening study DCP 001

NCT#03418961

S1501 is temporarily closed to accrual, effective February 1, 2024 at 12pm Pacific Time.

S1501,  Arm 3 is permanently closed to accrual, effective July 29, 2021, at 11:59pm Pacific Time.

SWOG S1703

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

NCT#03723928

Eligible for screening study DCP 001

SWOG S1803

Primary Category:

Treatment Protocols

Disease Category:

Multiple Myeloma

Status:

Open

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Eligible for screening study DCP 001

Occupational Report & Pregnancy Report consent forms available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consents and for any questions.

S1803 is open to accrual, effective Novmember 21, 2023, with the implementation of Revision 8.

NCT#04071457

SWOG S2007

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

NCT#04647916

 

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

WAKE FOREST WF-2201

Primary Category:

Radiation Oncology

Disease Category:

Brain Metastatic, Breast, Breast Metastatic, Genitourinary, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Melanoma, Metastatic Melanoma, Renal, Renal Metastatic, Skin

Status:

New, Open

Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE)

NCT#05703269

Eligible for screening study DCP 001

Neuroendocrine

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Other

ALLIANCE A032002

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Other

Status:

Open

Phase II Randomized Trial of Immunotherapy Versus Immunotherapy and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (IMMORTAL)

NCT#04936230

A032002 is reopened to accrual, effective December 19, 2023, with the implementation of Update 3.

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

DCP 001

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Other

Status:

Open

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Patients can be registered to DCP-001 up to 4 weeks after eligibility for and enrollment status to the trial for which the patient is being screened for has been determined. Participants may be screened for more than one clinical trial.

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

NRG BR008

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Adjuvant Breast, Breast, Breast Neoadjuvant

Status:

New, Open

A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)

NCT#05705401

Eligible for screening study DCP 001

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

SWOG S2206

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

New, Open

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

NCT#06058377

SWOG S2212

Primary Category:

Surgical Protocols, Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

New, Open

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

NCT#05929768

Sarcoma

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Skin

ALLIANCE A091903

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

Open

A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma

A091903 is reopened to accrual with the implementation of Updat4, effective March 5, 2024.

NCT#05111574

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ALLIANCE A222004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid Metastatic, Cervical Metastatic, Colon Metastatic, Endometrial Metastatic, Esophageal Metastatic, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck Metastatic, Lung, Lung - Non-Small Cell Metastatic, Metastatic Melanoma, Neuroendocrine, Pancreatic Metastatic, Prostate Metastatic, Rectal Metastatic, Renal Metastatic, Skin, Stomach Metastatic

Status:

New, Open

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

NCT#04939090

Site staff should complete the information required on Site Activation Form (Click Here) and submit it to the Alliance Pharmaceutical Affairs Manager at pharmaffairs@alliancenctn.org, along with a copy of the site’s pharmacy or physician license.

ECOG-ACRIN EA6141

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

Open

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

NCT#02339571

This protocol has additional training requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.

Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21

 

ECOG-ACRIN EA6174

Primary Category:

Treatment Protocols

Disease Category:

Skin

Status:

Temporarily Closed

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial

NCT#03712605

Eligible for screening study DCP 001

EA6174 is temporarily closed to accrual, effective March 31, 2023.

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S2000

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

Open

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

NCT#04511013

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2101

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

Open

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) – A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study

NCT#05136196

S2101 is reopened to accrual with implementation of Revision 3, effective January  16, 2024.

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

WAKE FOREST WF-2201

Primary Category:

Radiation Oncology

Disease Category:

Brain Metastatic, Breast, Breast Metastatic, Genitourinary, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Melanoma, Metastatic Melanoma, Renal, Renal Metastatic, Skin

Status:

New, Open

Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE)

NCT#05703269

Eligible for screening study DCP 001

Solid tumor or Hematologic Malignancy

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

Thyroid

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A211901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Colon, Colon Metastatic, Diffuse Large B-cell Lymphoma, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Follicular Lymphoma, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Hodgkin Lymphoma, Leukemia, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Mantle Cell Lymphoma, Melanoma, Mesothelioma, Metastatic Melanoma, Multiple Myeloma, Myelodysplastic Syndrome, Neuroendocrine, Non-Hodgkin Lymphoma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, T-cell Lymphoma, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

NCT#05008848

Eligible for screening study DCP 001

Complete “Registration & On Study Information” form below with participant at time of consent.  Send with all other initial materials for registration to MCC.

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

Eligible for screening study DCP 001

NCT#05334069

A212102 Thyroid, Melanoma, and Sarcoma cancer cohorts are closed to accrual effective November 15, 2023, with the release of Update 2.

A212102 is reopened to non-white male participants without a cancer diagnosis, effective August 1, 2023, with the implementation of Update 1.

A212102 is temporarily suspended to enrollment of participants without a cancer diagnosis. effective February 22, 2023.

A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.

ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4, EAY191-N5, and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001

ECOG-ACRIN EAY191-E4

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Temporarily Closed

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

(See required screening study ECOG-ACRIN EAY191)

NCT#05554341

EAY191-E4 is temporarily closed to accrual, effective January 12, 2024.

ECOG-ACRIN EAY191-E5

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

New, Open

A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

NCT#05638295

(See required screening study ECOG-ACRIN EAY191)

SWOG EAY191-S3

Primary Category:

Treatment Protocols

Disease Category:

Anal, Bladder, Brain, Brain Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, GYN Other, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

NCT#05554380

(See required screening study ECOG-ACRIN EAY191)

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606